IP Library Granted Patent US 10,620,193
Granted Patent B2
US 10,620,193 · App. 15/951,720 · Granted Apr 14, 2020

Reducing optical interference in a fluidic device

Inventors: Ian Gibbons (Newark, CA); Michael O'Connell (San Jose, CA)
Assignee: Theranos IP Company, LLC
G01N33/5304B01L3/5027B01L3/502715B01L2200/16B01L2300/069B01L2300/0816B01L2300/0887B01L2400/0406B01L2400/0487Y10T156/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,620,193
App. No.
15/951,720
Granted
Apr 14, 2020
Kind
B2
Abstract

This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.

Claims (36)

1. A system for detecting an analyte in a sample of bodily fluid, the system comprising:

a fluidic device having an identifier and a housing for running an assay to detect the analyte in the sample, the fluidic device further comprising: at least one sample collection unit, an assay assembly, and a waste assembly, wherein the assay assembly comprises at least one reagent for generating a fluorescent signal indicative of the presence of the analyte in the sample of bodily fluid;

a reader assembly comprising an identification detector, a communication assembly, a controller, and a detection assembly, wherein the fluidic device is configured to be inserted into the reader assembly, and

wherein the identification detector is configured to:

detect the identifier of the fluidic device; and

transmit the identifier to the communication assembly,

wherein the communication assembly is configured to:

receive, from an external device, a protocol to execute on the fluidic device selected in response to detection of the identifier, wherein the protocol comprises instructions to the controller to run the assay;

wherein the detection assembly is configured to detect the analyte in the sample by detecting the fluorescent signal based on the instructions in the protocol received from the external device, and

wherein the waste assembly comprises a quenching site and a quenching agent that inhibits an enzymatic reaction between the at least one reagent and a second reagent, thereby reducing interference with the fluorescent signal.

2. The system of claim 1 , wherein the communication assembly is further configured to:

receive the protocol from the external device in response to transmitting the identifier to the external device.

3. The system of claim 1 , wherein the communication assembly is further configured to:

transmit the fluorescent signal to the external device.

4. The system of claim 1 , wherein the detection assembly comprises one of a digital camera, a charge coupled device (CCD), a photomultiplier, and a phototube.

5. The system of claim 1 , wherein the assay assembly further comprises a reagent chamber, a reaction site, and an additional fluidic channel that connects the reagent chamber with the reaction site.

6. The system of claim 1 , wherein the quenching site further comprises an absorbent material saturated with the quenching agent.

7. A system for detecting an analyte in a sample of bodily fluid, the system comprising:

a fluidic device having a housing for running a immunoassay to detect the analyte in the sample of bodily fluid within the housing, the fluidic device comprising:

at least one sample collection unit;

an assay assembly in fluidic communication with the at least one sample collection unit, wherein the assay assembly comprises at least one reagent for generating a fluorescent signal indicative of the presence of the analyte in the sample of bodily fluid; and

a waste chamber, and

a reader assembly comprising an identification detector, a communication assembly, a controller, and a detection assembly, wherein the fluidic device is configured to be inserted into the reader assembly,

wherein the identification detector is configured to:

detect an identifier of the fluidic device; and

transmit the identifier to the communication assembly,

wherein the communication assembly is configured to:

receive, from an external device, a protocol to execute on the fluidic device selected in response to detection of the identifier, wherein the protocol comprises instructions to the controller to run the immunoassay;

wherein the detection assembly is configured to detect the analyte in the sample by detecting the fluorescent signal based on the instructions in the protocol received from the external device; and

wherein the waste assembly comprises a quenching site and a quenching agent that inhibits an enzymatic reaction between the at least one reagent and a second reagent, thereby reducing interference of the fluorescent signal.

8. The system of claim 7 , wherein the communication assembly is further configured to:

receive the protocol from the external device in response to transmitting the identifier to the external device.

9. The system of claim 7 , wherein the detection assembly comprises one or more digital cameras, charge coupled devices (CCDs), photomultipliers, or phototubes.

10. The system of claim 7 , wherein the assay assembly further comprises at least one reagent chamber, at least one reaction site, and at least one additional fluidic channel that connects the at least one reagent chamber with the at least one reaction site.

11. The system of claim 7 , wherein the detection assembly is further configured to:

detect a concentration of the analyte in the sample based on the fluorescent signal.

Assignments (3)
CHANGE OF NAME Recorded Apr 7, 2020
From: THERANOS IP COMPANY LLC
To: LABRADOR DIAGNOSTICS LLC
Reel/Frame 052329/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: GIBBONS, IAN; O'CONNELL, MICHAEL
To: THERANOS, INC.
Reel/Frame 052034/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2020
From: THERANOS, INC.
To: THERANOS IP CO., LLC
Reel/Frame 052115/0033 →
Continuity (4)
Continuation 13915362 · Jun 11, 2013
Continuation 13188288 · Jul 21, 2011
Continuation 11549558 · Oct 13, 2006
Related Publication 20180231534A1 · Aug 16, 2018